Comparative Pharmacology
Head-to-head clinical analysis: JUNEL 1 5 30 versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JUNEL 1 5 30 versus PIRMELLA 7 7 7.
JUNEL 1.5/30 vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin release (FSH, LH) via estrogen and progestin negative feedback, inhibiting ovulation. Changes cervical mucus viscosity and endometrial lining to impede sperm penetration and implantation.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
EE: terminal half-life ~17 ± 8 hours; NET: terminal half-life ~8 ± 1 hours. Steady-state achieved within ~2-3 cycles.
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Ethinyl estradiol (EE) and norethindrone (NET) are excreted in urine (40-60% as metabolites) and feces (20-30% as metabolites). NET is also excreted in bile and undergoes enterohepatic recirculation.
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive